Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013:2013:802512.
doi: 10.1155/2013/802512. Epub 2013 Mar 20.

In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in relation to tumor growth

Affiliations

In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in relation to tumor growth

Chinyere Nwabugwu et al. Comput Math Methods Med. 2013.

Abstract

The dependence on the overexpression of a single oncogene constitutes an exploitable weakness for molecular targeted therapy. These drugs can produce dramatic tumor regression by targeting the driving oncogene, but relapse often follows. Understanding the complex interactions of the tumor's multifaceted response to oncogene inactivation is key to tumor regression. It has become clear that a collection of cellular responses lead to regression and that immune-mediated steps are vital to preventing relapse. Our integrative mathematical model includes a variety of cellular response mechanisms of tumors to oncogene inactivation. It allows for correct predictions of the time course of events following oncogene inactivation and their impact on tumor burden. A number of aspects of our mathematical model have proven to be necessary for recapitulating our experimental results. These include a number of heterogeneous tumor cell states since cells following different cellular programs have vastly different fates. Stochastic transitions between these states are necessary to capture the effect of escape from oncogene addiction (i.e., resistance). Finally, delay differential equations were used to accurately model the tumor growth kinetics that we have observed. We use this to model oncogene addiction in MYC-induced lymphoma, osteosarcoma, and hepatocellular carcinoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mathematical model of cellular states. Former model shown in gold with additions shown in blue. The arrows with slashes corresponding to ±dox indicate that this is an independent variable controlled experimentally. The arrows representing proliferative loops have an implicit state during proliferation representing the mitotic phase of the cell cycle.
Figure 2
Figure 2
Tumor regression and relapse kinetics as measured by bioluminescence imaging. Wildtype (WT) are immunocompetent mice while SCID and RAG2−/−cγc−/− are immunodeficient mice. Excerpted from [27].
Figure 3
Figure 3
Set of equations represented by the model shown in Figure 1. B(n, p) is a binomial random variable of n the Bernoilli trials with probability of success p. K are rate constants independent of the time step size. Note that all the main variables are a function of t shortened for the sake of clarity. For example, M is M(t).
Figure 4
Figure 4
Simulated tumor growth kinetics with no delay and no escape of tumor cells from the conditional control of MYC due to an intact immune system. Note the lack of delay in the decrease of tumor cells as is observed in days 0–5.
Figure 5
Figure 5
Simulated tumor growth kinetics with no escape of tumor cells from the conditional control of MYC due to an intact immune system. Note the correctly modeled delay in tumor cell death as is observed in Figure 2.
Figure 6
Figure 6
Simulated tumor growth kinetics with a low (but nonzero) rate of tumor cells escaping from conditional control of MYC due to a compromised immune system. Note the early growth kinetics of the escaped tumor cell population demonstrates stochastic variability that affects the timing of the relapse.
Figure 7
Figure 7
Variability in relapse kinetics captured using 20 stochastic simulations.

Similar articles

References

    1. Weinstein IB, Begemann M, Zhou P, et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clinical Cancer Research. 1997;3(12):2696–2702. - PubMed
    1. Demetri GD. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571) European Journal of Cancer. 2002;38:S52, supplement–S59. - PubMed
    1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine. 2001;344(14):1031–1037. - PubMed
    1. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England Journal of Medicine. 2002;346(9):645–652. - PubMed
    1. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129–141. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources